Potential for amino acids supplementation during inflammatory bowel diseases

Inflammatory Bowel Diseases

Volumn 16, Issue 3, 2010, Pages 518-524

  Cöeffier, Moïse ^a   Marion Letellier, Rachel ^a   Déchelotte, Pierre ^a  

^a ROUEN UNIVERSITY HOSPITAL   (France)

Author keywords

Arginine; Crohn's disease; Glutamine; Nutrition; Ulcerative colitis

Indexed keywords

5 AMINOSALICYLTAURINE; AMINO ACID; AMINOSALICYLIC ACID; AMINOSALICYLIC ACID DERIVATIVE; ARGININE; CYSTEINE; GLUTAMINE; GLYCINE; HISTIDINE; NITRIC OXIDE; POLYAMINE; TAURINE; UNCLASSIFIED DRUG;

AMINO ACID SUPPLEMENTATION; AMINO ACID SYNTHESIS; ANTIINFLAMMATORY ACTIVITY; BIOLOGICAL THERAPY; COLITIS; COMPETITIVE INHIBITION; CROHN DISEASE; DIET SUPPLEMENTATION; DRUG MEGADOSE; ENTERIC FEEDING; ENTERITIS; HUMAN; IMMUNOMODULATION; INTESTINE CELL; MALNUTRITION; NONHUMAN; NUTRITIONAL SUPPORT; PRIORITY JOURNAL; REMISSION; REVIEW; THERAPY EFFECT;

AMINO ACIDS; COLITIS, ULCERATIVE; CROHN DISEASE; DIETARY SUPPLEMENTS; HUMANS; MALNUTRITION;

EID: 77149164186     PISSN: 10780998     EISSN: 15364844     Source Type: Journal    
DOI: 10.1002/ibd.21017     Document Type: Review

References (81)

1. Isaacs KL, Sartor RB, Haskill S. Cytokine messenger RNA profiles in inflammatory bowel disease mucosa detected by polymerase chain reaction amplification. Gastroenterology. 1992;103:1587-1595.
2. Podolsky DK. Inflammatory bowel disease. N Engl J Med. 2002;347: 417-429.
3. Reimund JM, Wittersheim C, Dumont S, et al. Increased production of tumour necrosis factor-alpha interleukin-1 beta, and interleukin-6 by morphologically normal intestinal biopsies from patients with Crohn's disease. Gut. 1996;39:684-689.
4. Nieves C Jr, Langkamp-Henken B. Arginine and immunity: a unique perspective. Biomed Pharmacother. 2002;56:471-482.
5. Powell-Tuck J. Nutritional interventions in critical illness. Proc Nutr Soc. 2007;66:16-24.
6. Bourreille A, Humbert B, Maugere P, et al. Glutamine metabolism in Crohn's disease: a stable isotope study. Clin Nutr. 2004;23:1167-1175.
7. Sido B, Seel C, Hochlehnert A, et al. Low intestinal glutamine level and low glutaminase activity in Crohn's disease: a rational for glutamine supplementation? Dig Dis Sci. 2006;51:2170-2179.
8. Coeffier M, Dechelotte P. The role of glutamine in intensive care unit patients: mechanisms of action and clinical outcome. Nutr Rev. 2005; 63:65-69.
9. Akobeng AK, Thomas AG. Enteral nutrition for maintenance of remission in Crohn's disease. Cochrane Database Syst Rev. 2007: CD005984.
10. Ameho CK, Adjei AA, Harrison EK, et al. Prophylactic effect of dietary glutamine supplementation on interleukin 8 and tumour necrosis factor alpha production in trinitrobenzene sulphonic acid induced colitis. Gut. 1997;41:487-493.
11. Israeli E, Berenshtein E, Wengrower D, et al. Prophylactic administration of topical glutamine enhances the capability of the rat colon to resist inflammatory damage. Dig Dis Sci. 2004;49:1705-1712.
12. Giris M, Erbil Y, Dogru-Abbasoglu S, et al. The effect of heme oxygenase-1 induction by glutamine on TNBS-induced colitis. The effect of glutamine on TNBS colitis. Int J Colorectal Dis. 2007;22:591-599.
13. Vicario M, Amat C, Rivero M, et al. Dietary glutamine affects mucosal functions in rats with mild DSS-induced colitis. J Nutr. 2007;137: 1931-1937.
14. Arndt H, Kullmann F, Reuss F, et al. Glutamine attenuates leukocyteendothelial cell adhesion in indomethacin-induced intestinal inflammation in the rat. JPEN J Parenter Enteral Nutr. 1999;23:12-18.
15. Basivireddy J, Jacob M, Balasubramanian KA. Oral glutamine attenuates indomethacin-induced small intestinal damage. Clin Sci (Lond). 2004;107:281-289.
16. Fillmann H, Kretzmann NA, San-Miguel B, et al. Glutamine inhibits over-expression of pro-inflammatory genes and down-regulates the nuclear factor kappaB pathway in an experimental model of colitis in the rat. Toxicology. 2007;236:217-226.
17. Neilly PJ, Gardiner KR, Kirk SJ, et al. Topical glutamine therapy in experimental inflammatory bowel disease. Clin Nutr. 1995;14: 283-287.
18. Scheppach W, Dusel G, Kuhn T, et al. Effect of L-glutamine and n-butyrate on the restitution of rat colonic mucosa after acid induced injury. Gut. 1996;38:878-885.
19. Evans ME, Jones DP, Ziegler TR. Glutamine prevents cytokineinduced apoptosis in human colonic epithelial cells. J Nutr. 2003;133: 3065-3071.
20. Coeffier M, Claeyssens S, Hecketsweiler B, et al. Enteral glutamine stimulates protein synthesis and decreases ubiquitin mRNA level in human gut mucosa. Am J Physiol Gastrointest Liver Physiol. 2003; 285:G266-273.
21. Phanvijhitsiri K, Musch MW, Ropeleski MJ, et al. Heat induction of heat shock protein 25 requires cellular glutamine in intestinal epithelial cells. Am J Physiol Cell Physiol. 2006;291:C290-299.
22. Coeffier M, Le Pessot F, Leplingard A, et al. Acute enteral glutamine infusion enhances heme oxygenase-1 expression in human duodenal mucosa. J Nutr. 2002;132:2570-2573.
23. Cavicchi M, Gibbs L, Whittle BJ. Inhibition of inducible nitric oxide synthase in the human intestinal epithelial cell line, DLD-1, by the inducers of heme oxygenase 1, bismuth salts, heme, and nitric oxide donors. Gut. 2000;47:771-778.
24. Wang WP, Guo X, Koo MW, et al. Protective role of heme oxygenase-1 on trinitrobenzene sulfonic acid-induced colitis in rats. Am J Physiol Gastrointest Liver Physiol. 2001;281:G586-594.
25. Paul G, Bataille F, Obermeier F, et al. Analysis of intestinal haem-oxygenase-1 (HO-1) in clinical and experimental colitis. Clin Exp Immunol. 2005;140:547-555.
26. Li N, Lewis P, Samuelson D, et al. Glutamine regulates Caco-2 cell tight junction proteins. Am J Physiol Gastrointest Liver Physiol. 2004; 287:G726-733.
27. Poritz LS, Garver KI, Green C, et al. Loss of the tight junction protein ZO-1 in dextran sulfate sodium induced colitis. J Surg Res. 2007;140: 12-19.
28. Kessel A, Toubi E, Pavlotzky E, et al. Treatment with glutamine is associated with down-regulation of Toll-like receptor-4 and myeloid differentiation factor 88 expression and decrease in intestinal mucosal injury caused by lipopolysaccharide endotoxaemia in a rat. Clin Exp Immunol. 2008;151:341-347.
29. Yassad A, Husson A, Bion A, et al. Synthesis of interleukin 1beta and interleukin 6 by stimulated rat peritoneal macrophages: modulation by glutamine. Cytokine. 2000;12:1288-1291.
30. Yaqoob P, Calder PC. Cytokine production by human peripheral blood mononuclear cells: differential senstivity to glutamine availability. Cytokine. 1998;10:790-794.
31. Parlesak A, Negrier I, Neveux N, et al. Arginine does not exacerbate markers of inflammation in cocultures of human enterocytes and leukocytes. J Nutr. 2007;137:106-111.
32. Marion R, Coeffier M, Lemoulan S, et al. L-Arginine modulates CXC chemokines in the human intestinal epithelial cell line HCT-8 by the NO pathway. Biochimie. 2005;87:1048-1055.
33. Rhoads JM, Chen W, Gookin J, et al. Arginine stimulates intestinal cell migration through a focal adhesion kinase dependent mechanism. Gut. 2004;53:514-522.
34. Marion R, Coeffier M, Leplingard A, et al. Cytokine-stimulated nitric oxide production and inducible NO-synthase mRNA level in human intestinal cells: lack of modulation by glutamine. Clin Nutr. 2003;22: 523-528.
35. Marion R, Coeffier MM, Gargala G, et al. Glutamine and CXC chemokines IL-8, Mig, IP-10 and I-TAC in human intestinal epithelial cells. Clin Nutr. 2004;23:579-585.
36. Clark EC, Patel SD, Chadwick PR, et al. Glutamine deprivation facilitates tumour necrosis factor induced bacterial translocation in Caco-2 cells by depletion of enterocyte fuel substrate. Gut. 2003;52: 224-230.
37. Liboni K, Li N, Neu J. Mechanism of glutamine-mediated amelioration of lipopolysaccharide-induced IL-8 production in Caco-2 cells. Cytokine. 2004;26:57-65.
38. Liboni KC, Li N, Scumpia PO, et al. Glutamine modulates LPSinduced IL-8 production through IkappaB/NF-kappaB in human fetal and adult intestinal epithelium. J Nutr. 2005;135:245-251.
39. Chow A, Zhang R. Glutamine reduces heat shock-induced cell death in rat intestinal epithelial cells. J Nutr. 1998;128:1296-1301.
40. Wischmeyer PE, Musch MW, Madonna MB, et al. Glutamine protects intestinal epithelial cells: role of inducible HSP70. Am J Physiol. 1997;272:G879-884.
41. Ehrenfried JA, Chen J, Li J, et al. Glutamine-mediated regulation of heat shock protein expression in intestinal cells. Surgery. 1995;118: 352-356; discussion 356-357.
42. Fitzgerald AJ, Rai PS, Marchbank T, et al. Reparative properties of a commercial fish protein hydrolysate preparation. Gut. 2005;54: 775-781.
43. Son DO, Satsu H, Shimizu M. Histidine inhibits oxidative stress- and TNF-alpha-induced interleukin-8 secretion in intestinal epithelial cells. FEBS Lett. 2005;579:4671-4677.
44. Zhao Z, Satsu H, Fujisawa M, et al. Attenuation by dietary taurine of dextran sulfate sodium-induced colitis in mice and of THP-1-induced damage to intestinal Caco-2 cell monolayers. Amino Acids. 2008;35: 217-224.
45. Huang Y, Li N, Liboni K, et al. Glutamine decreases lipopolysaccharide- induced IL-8 production in Caco-2 cells through a non-NF-kappaB p50 mechanism. Cytokine. 2003;22:77-83.
46. Hubert-Buron A, Leblond J, Jacquot A, et al. Glutamine pretreatment reduces IL-8 production in human intestinal epithelial cells by limiting IkappaBalpha ubiquitination. J Nutr. 2006;136:1461-1465.
47. Kretzmann NA, Fillmann H, Mauriz JL, et al. Effects of glutamine on proinflammatory gene expression and activation of nuclear factor kappa B and signal transducers and activators of transcription in TNBS-induced colitis. Inflamm Bowel Dis. 2008;14:1504-1513.
48. Rhoads JM, Argenzio RA, Chen W, et al. Glutamine metabolism stimulates intestinal cell MAPKs by a cAMP-inhibitable, Raf-independent mechanism. Gastroenterology. 2000;118:90-100.
49. Sato N, Moore FA, Kone BC, et al. Differential induction of PPAR-c by luminal glutamine and iNOS by luminal arginine in the rodent postischemic small bowel. Am J Physiol Gastrointest Liver Physiol. 2006;290:G616-623.
50. Brasse-Lagnel C, Lavoinne A, Loeber D, et al. Glutamine and interleukin-1beta interact at the level of Sp1 and nuclear factor-kappaB to regulate argininosuccinate synthetase gene expression. FEBS J. 2007; 274:5250-5262.
51. Lecleire S, Hassan A, Marion-Letellier R, et al. Combined glutamine and arginine decrease proinflammatory cytokine production by biopsies from Crohn's patients in association with changes in NF-jB and p38 MAPK pathways. J Nutr. 2008;138:2481-2486.
52. Miralles-Barrachina O, Savoye G, Belmonte-Zalar L, et al. Low levels of glutathione in endoscopic biopsies of patients with Crohn's colitis: the role of malnutrition. Clin Nutr. 1999;18:313-317.
53. Belmonte L, Coeffier M, Le Pessot F, et al. Effects of glutamine supplementation on gut barrier, glutathione content and acute phase response in malnourished rats during inflammatory shock. World J Gastroenterol. 2007;13:2833-2840.
54. Harward TR, Coe D, Souba WW, et al. Glutamine preserves gut glutathione levels during intestinal ischemia/reperfusion. J Surg Res. 1994;56:351-355.
55. Coeffier M, Miralles-Barrachina O, Le Pessot F, et al. Influence of glutamine on cytokine production by human gut in vitro. Cytokine. 2001;13:148-154.
56. Coeffier M, Marion R, Leplingard A, et al. Glutamine decreases interleukin-8 and interleukin-6 but not nitric oxide and prostaglandins e(2) production by human gut in-vitro. Cytokine. 2002;18:92-97.
57. Coeffier M, Marion R, Ducrotte P, et al. Modulating effect of glutamine on IL-1beta-induced cytokine production by human gut. Clin Nutr. 2003;22:407-413.
58. Den Hond E, Hiele M, Peeters M, et al. Effect of long-term oral glutamine supplements on small intestinal permeability in patients with Crohn's disease. JPEN J Parenter Enteral Nutr. 1999;23:7-11.
59. Akobeng AK, Miller V, Stanton J, et al. Double-blind randomized controlled trial of glutamine-enriched polymeric diet in the treatment of active Crohn's disease. J Pediatr Gastroenterol Nutr. 2000;30:78-84.
60. Ockenga J, Borchert K, Stuber E, et al. Glutamine-enriched total parenteral nutrition in patients with inflammatory bowel disease. Eur J Clin Nutr. 2005;59:1302-1309.
61. Tsune I, Ikejima K, Hirose M, et al. Dietary glycine prevents chemical-induced experimental colitis in the rat. Gastroenterology. 2003; 125:775-785.
62. Wischmeyer P, Pemberton JH, Phillips SF. Chronic pouchitis after ileal pouch-anal anastomosis: responses to butyrate and glutamine suppositories in a pilot study. Mayo Clin Proc. 1993;68:978-981.
63. Coeffier M, Hecketsweiler B, Hecketsweiler P, et al. Effect of glutamine on water and sodium absorption in human jejunum at baseline and during PGE1-induced secretion. J Appl Physiol. 2005;98: 2163-2168.
64. Wu G, Morris SM Jr. Arginine metabolism: nitric oxide and beyond. Biochem J. 1998;336(Pt1):1-17.
65. Kolios G, Valatas V, Ward SG. Nitric oxide in inflammatory bowel disease: a universal messenger in an unsolved puzzle. Immunology. 2004;113:427-437.
66. Horowitz S, Binion DG, Nelson VM, et al. Increased arginase activity and endothelial dysfunction in human inflammatory bowel disease. Am J Physiol Gastrointest Liver Physiol. 2007;292:G1323-1336.
67. Armstrong AM, Campbell GR, Gannon C, et al. Oral administration of inducible nitric oxide synthase inhibitors reduces nitric oxide synthesis but has no effect on the severity of experimental colitis. Scand J Gastroenterol. 2000;35:832-838.
68. Vardareli E, Dundar E, Angin K, et al. Effects of intrarectal and intraperitoneal N(G)-nitro-L-arginine methyl ester treatment in 2,4,6-trinitrobenzenesulfonic acid induced colitis in rats. Exp Toxicol Pathol. 2003;55:271-276.
69. Lecleire S, Coeffier M, Leblond J, et al. Modulation of nitric oxide and cytokines production by L-arginine in human gut mucosa. Clin Nutr. 2005;24:353-359.
70. Moinard C, Cynober L, de Bandt JP. Polyamines: metabolism and implications in human diseases. Clin Nutr. 2005;24:184-197.
71. Chung DH, Evers BM, Townsend CM Jr, et al. Role of polyamine biosynthesis during gut mucosal adaptation after burn injury. Am J Surg. 1993;165:144-149.
72. Sukumar P, Loo A, Magur E, et al. Dietary supplementation of nucleotides and arginine promotes healing of small bowel ulcers in experimental ulcerative ileitis. Dig Dis Sci. 1997;42:1530-1536.
73. Mane J, Fernandez-Banares F, Ojanguren I, et al. Effect of L-arginine on the course of experimental colitis. Clin Nutr. 2001;20:415-422.
74. Sherman H, Chapnik N, Froy O. Albumin and amino acids upregulate the expression of human beta-defensin 1. Mol Immunol. 2006;43: 1617-1623.
75. Exner R, Tamandl D, Goetzinger P, et al. Perioperative GLY-GLN infusion diminishes the surgery-induced period of immunosuppression: accelerated restoration of the lipopolysaccharide-stimulated tumor necrosis factor-alpha response. Ann Surg. 2003;237:110-115.
76. Yamashina S, Ikejima K, Enomoto N, et al. Glycine as a therapeutic immuno-nutrient for alcoholic liver disease. Alcohol Clin Exp Res. 2005;29:162S-165S.
77. Andou A, Hisamatsu T, Okamoto S, et al. 71. Dietary histidine ameliorates murine colitis by inhibition of pro-inflammatory cytokine production from macrophages. Gastroenterology. 2009;136:564-574.
78. Oz HS, Chen TS, Nagasawa H. Comparative efficacies of 2 cysteine prodrugs and a glutathione delivery agent in a colitis model. Transl Res. 2007;150:122-129.
79. Son MW, Ko JI, Doh HM, et al. Protective effect of taurine on TNBS-induced inflammatory bowel disease in rats. Arch Pharm Res. 1998;21:531-536.
80. Jung Y, Kim HH, Kim H, et al. Evaluation of 5-aminosalicyltaurine as a colon-specific prodrug of 5-aminosalicylic acid for treatment of experimental colitis. Eur J Pharm Sci. 2006;28:26-33.
81. Kim H, Jeon H, Kong H, et al. A molecular mechanism for the antiinflammatory effect of taurine-conjugated 5-aminosalicylic acid in inflamed colon. Mol Pharmacol. 2006;69:1405-1412.